Summary.
A deficiency in the activity of uroporphyrinogen decarboxylase (UROD), the fifth enzyme of the haem biosynthetic pathway, is found in familial porphyria cutanea tarda (F-PCT) and hepatoerythropoietic porphyria (HEP). A new mutation (R292G) and a deletion have been found in a pedigree with two HEP patients (two sisters). The R292G mutation was not detected in 13 unrelated affected patients with F-PCT, so it appears to be uncommon. The possibility that the arginine 292 may participate at the active site of the enzyme is discussed. A summary of the 7 mutations/deletions found in the UROD gene with their frequency is presented.
that is very rapidly degraded in the presence of cell lysate (de Verneuil et al. 1986a ). Another point mutation (E167K, Romana et al. 1991 ) has been recently described in another HEP patient. Three different mutations have been described in F-PCT. Interestingly, one mutation occurs at the same position as the HEP G281E mutation, but involves the substitution of a Val rather than a Glu (Garey et al. 1989) . Two splice site mutations in the UROD gene have also been described in F-PCT (Garey et al. 1990) .
In this paper, we describe the characterization of a new mutation and a deletion in two HEP patients from the same family.
Introduction
Hepatoerythropoietic porphyria (HEP) is a rare homozygous form of familial porphyria cutanea tarda (F-PCT) that occurs early in infancy (for a review, see Kappas et al. 1988) . The characteristic enzyme deficiency is a profound decrease in the activity of uroporphyrinogen decarboxylase (UROD), the fifth enzyme of the haem biosynthetic pathway (Elder et al. 1981; Lazaro et al. 1984) , whereas the enzyme activity in F-PCT is about 50% of the normal level (Kushner et al. 1976; de Verneuil et al. 1978) . Evidence for heterogeneity in inherited UROD deficiency has been well documented at the protein level with CRIM (cross-reactive immunological material)-positive (presence of an abnormal immunologically detectable protein) and CRIM-negative (absence of the abnormal protein) cases de Verneuil et al. 1984 de Verneuil et al. , 1986b Toback et al. 1987; Fujita et al. 1987; Koszo et al. 1990) .
We have characterized the first mutation (G281E) in one of the CRIM-negative family leading to a protein
Materials and methods

Cases studied
The patients consisted of two sisters (patients I and II) with HEP from non-consanguineous parents of Caucasian origin (Holland) (Fig. 1) 
In vitro amplification
RNA was isolated from lymphocytes by non-ionic detergent lysis (Sambrook et al. 1989 
cDNA cloning and sequencing
The polymerase chain reaction (PCR) products were subcloned into the pGEM7Zf+ vector (Promega Biotec, Madison, WI). The DNA was purified by gel filtration on an S-200 column (Pharmacia, Sweden) and subcloned into an EcoRI-HindIII-digested vector.
Different independent clones were then sequenced by the dideoxychain termination method (Sequenase sequencing kit, USB Corporation).
Oligonucleotide hybridization analysis
Amplified fragments were slot-blotted onto a nylon membrane and then hybridized to allele-specific oligonucleotides (ASOs). The sequence of the two ASOs are as follows: 292N: 5'-AGAAAGCCCGGTAAGCC-3' and 292M: 5'-AGAAAGCCG-GGTAAGCC-Y. Probe labelling, hybridization (56~ and posthybridization filter washes (58~ were carried out according to the method described previously (Grandchamp et al. 1989) , except that oligonucleotides and temperatures were varied as mentioned above.
In vitro degradation studies
RNA was made by transcribing cDNA in vitro using T7 RNA polymerase after linearization of the plasmid with HindIII. The RNA was then translated in vitro in a micrococcal nuclease-treated rabbit reticulocyte lysate in the presence of [35S] methionine (de Verneuil et al. 1986b) . Aliquots (5 ~tl) of the translation mixture were incubated at 37~ for 0, 24, 48 and 80 h in the presence of 15 ~tl sonicated lymphoblastoid cell lysate (2 mg/ml). Translation products were analysed by SDS (sodium dodecylsulphate) polyacrylamide gel (10%) eleetrophoresis.
Results
The , leading to the conclusion that these patients carry ( a n ) o t h e r mutation(s). Cloning and sequencing of the amplified f r a g m e n t from patient I r e v e a l e d that two i n d e p e n d e n t clones carry a C to G change at nucleotide 892, leading to a A r g 292--~Gly substitution (R292G) in the protein. N o o t h e r was digested with Pstl and electrophoresed in a 1% agarose gel. The DNA was denatured, transferred to a nylon membrane (Hybond-N +, Amersham) and hybridized with either [32p] UROD cDNA or porphobilinogen deaminase (PBGD) cDNA probes. Lanes 1-3 DNA from the father, the mother and a control, respectively base change was found. We confirmed that this nucleotide substitution suppresses a Sinai site ( 5 ' -C C C G G G -3 ' ) in the c D N A by direct digestion of the PCR-amplified products with Sinai (data not shown). This restriction site (position 890-895 on the cDNA; see Romeo et al. 1986 for the normal human sequence) corresponds to the exon 8-intron 8 boundary (Romana et al. 1987a ) and is not conserved in the genomic DNA. We therefore decided to confirm the mutation at the gene level by hybridization of an amplified genomic D N A fragment of 860bp (from intron 7 to exon 10) with ASOs (Fig. 3) , The normal oligonucleotide probe (292 N) hybridized to D N A from normal controls. The mutant probe (292 M) hybridized to amplified D N A from the patient, whereas no signal was found with the normal oligonucleotide, confirming the existence of the mutation at the genomic level.
At this point of the study, two hypotheses could have explained the results: either patient I is homozygous for the R292G mutation or she is heterozygous for this mutation and carries a deletion of the U R O D gene. A family study was then undertaken to clarify this point. Amplified genomic fragment from the mother hybridized with both probes (292N and 292M), confirming that she carries the R292G mutation. In contrast, the amplified fragment from the father hybridized only with the normal probe: this result indicates that the father carries a deletion that is not detectable by our PCR amplification. We then performed a Southern blot analysis in order to characterize the deletion of the U R O D gene (Fig. 4) . We could not find any fragments of an abnormal size from the D N A of the father with three different restriction enzymes ( E c o R I , HindIII, PstI) . However, a weaker signal was found for the specific fragment from the father compared with the mother, or a normal control, confirming the existence of a deleterious allele from the father.
In vitro translated [35S]-labelled normal and mutant U R O D proteins were exposed to lymphoblastoid cell lysates (for 0 h, 24 h, 48 h and 80 h) and then subjected to electrophoresis on polyacrylamide SDS gels. No signifi- cant difference in degradation between the normal and the mutant protein was found. We checked for the presence of the R292G mutation in 13 unrelated F-PCT patients by hybridization of specific genomic fragments with the ASOs. None of the 13 tested patients carries the mutation. Figure 5 is a summary of the different mutations/deletions found in the U R O D gene in H E P and F-PCT. The frequency of the mutations has been calculated from seven H E P patients from 7 unrelated families (14 mutated alleles) and from 13-20 F-PCT patients (13-20 mutated alleles). This frequency is not accurate because of the small number of families (the disease is very rare) and because of possible consanguinity. However, we can conclude from these results that a great heterogeneity exists among the mutations responsible for H E P or F-PCT in humans. Two different mutations (the G281E mutation for H E P and a splice site mutation that causes the deletion of exon 6 in F-PCT) appear to be more common.
Discussion
The present study describes a molecular analysis of the U R O D gene in two new H E P patients. The strategy that we used is as follows: extraction of total RNA from the lymphocytes of one of the patients allowed us to amplify in vitro the entire coding sequence in a single step of PCR. Because of the presence of amplified fragments that were normal in size, we have been able to determine that a point mutation (R292G) is present in the patient. This mutation has been confirmed at the DNA level by specific amplification of a part of the gene (from intron 7 to exon 10) and by hybridization with ASOs. A familial study revealed that the R292G mutation is present in the DNA of patient II and the mother, but not the father. Illegitimacy was excluded by a study of restriction fragment length polymorphisms of the HLADQ locus in the family. Because amplified DNA from both children did not hybridize with the normal 292N probe, the only explanation of the profound deficiency present in both children and the 50% deficiency present in the father's blood is a deletion of the UROD gene on one allele. Southern blot analysis did not detect any abnormally sized UROD gene fragments, leading to the conclusion that the deletion is large, at least more than 3 kb (corresponding to the size of the UROD gene explored by the cDNA probe). Chromosome walking from the 5' end and 3' end of the gene will be needed to characterize the deletion further. The mutation results in the presence, in the abnormal protein, of a glycine residue instead of an arginine. Interestingly, this arginine is a conserved amino acid in the rat (Romana et al. 1987b ) and in yeast proteins (R. Labbe-Bois, personal communication) (Fig. 6) . Kinetic data of crude or purified normal human, chicken and bovine UROD suggest that there may be between 2 and 4 active sites for the different sequential decarboxylations of uroporphyrinogen to coproporphyrinogen (de Verneuil et al. 1980 Kawanishi et al. 1983; Straka and Kushner 1983) . Experiments using SH-inactivating agents suggest that at least one cysteine is involved in the decarboxylation . It is probable that basic amino acids are also involved in the catalytic site or are important for the integrity of the protein, because of the high conservation of these residues (Fig. 6) . Chemical modification of cationic residues present in different enzymes of the haem pathway results in the rapid inactivation of the protein. This has been demonstrated for ferrochelatase (Dailey and Fleming 1986) and uroporphyrinogen III synthase (Hart et al. 1985) for arginyl residues, and for porphobilinogen deaminase (Miller et al. 1989 ) and aminolevulinate dehydratase (Gibbs and Jordan 1986) for lysyl residues. These considerations raise the possibility that the arginine 292 may participate at the active site of the enzyme by the formation of ionic bonds with the different acetic and/or propionic side chains of the substrate uroporphyrinogen. Isolation of normal and mutated proteins from over-expressing strains should allow us to study the three dimensional structure of the protein and to determine the different residues involved in the active site(s).
